Short-term Celebrex seems safe for osteoarthritis

	Tweet

The COX-2 inhibitor Celebrex (celecoxib) causes fewer gastrointestinal complications than traditional nonsteroidal anti-inflammatory painkillers or NSAIDs, without raising the risk of cardiovascular events, according to results of a large, prospective, 3-month trial.

Some clinical trials have demonstrated increased cardiovascular risk associated with other COX-2 inhibitors, which led to the withdrawal of two from the market—Vioxx (rofecoxib) and Bextra (valdecoxib). Results of one study suggested that Celebrex, given in large doses (800 mg/day) over prolonged periods of time, may also have a worse cardiovascular risk profile than nonspecific NSAIDs, whereas other studies showed no such risk.

The SUccessive Celecoxib Efficacy and Safety Study-1 (SUCCESS-1), conducted in 39 countries, enrolled 13,194 patients with osteoarthritis of the hip, knee or hand of at least 6 months duration.

The investigators, led by Dr. Gurkirpal Singh from Stanford University School of Medicine in California, randomized patients to Celebrex (100 or 200 mg twice daily), the NSAID naproxen (500 mg twice daily) or the NSAID diclofenac (50 mg twice daily). Treatment lasted for 12 weeks.

The researchers report in the American Journal of Medicine for March that all treatments were similarly effective in reducing pain. Moreover, Celebrex 100 mg twice daily was comparable to Celebrex 200 mg twice daily.

The incidence of serious upper gastrointestinal events was 1.0 per 100 patient-years in the NSAID groups and 0.2 per 100 patient-years in the Celebrex groups (odds ratio 6.02).

Although numerical differences were seen, there was no statistically significant difference between Celebrex and NSAIDs in any cardiovascular adverse event rate, except that the rate of heart failure was higher in the NSAID group.

When making recommendations for treatment of osteoarthritis, Singh’s group advises, “clinicians should consider a number of factors, including the risk for upper gastrointestinal events, duration of therapy, as well as costs, before deciding upon individual patient treatment.”

SOURCE: American Journal of Medicine, March 2006. 

RELATED STORIES:
Enbrel especially helpful for early arthritis   Weight loss may reduce arthritis disability   Ultrasound Makes for Speedy, Accurate Arthritis Care   Rheumatoid arthritis may be becoming milder   Women with Rheumatoid Arthritis Less Likely to Go into Remission   Acupuncture doesn’t reduce arthritis pain   Too much physical activity may lead to arthritis   Mental distress common in adults with arthritis   Sharp Drop In Stress Hormones May Set Stage For Arthritis, Multiple Sclerosis After Pregnancy   Early infections may increase arthritis risk   New arthritis drug free via Medicare   Exercise program improves symptoms in arthritis patients

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]